

AMENDMENTS TO THE CLAIMS

Claim 1 (currently amended). An article of manufacture comprising packaging material and a pharmaceutical composition contained within said packaging material, wherein said pharmaceutical composition is capable of ~~modulating~~ stimulating angiogenesis in a tissue associated with a disease condition, wherein said packaging material comprises a label which indicates that said pharmaceutical composition is administered to a patient for treating disease conditions by ~~modulating~~ stimulating angiogenesis, and wherein said pharmaceutical composition ~~comprises~~ consists essentially of at least about 0.1 weight percent of an isolated active or inactive Raf protein in a physiologically tolerable excipient or carrier therefore; wherein the active Raf protein is selected from the group consisting of c-Raf (SEQ ID NO: 2), a protein having the amino acid sequence corresponding to residues 306 through 648 of SEQ ID NO: 2, and Raf-caax (SEQ ID NO: 7); ~~and the inactive Raf protein is selected from the group consisting of a protein having the amino acid sequence corresponding to SEQ ID NO: 2 having an amino acid other than lysine at residue 375, and a protein having the amino acid sequence corresponding to residues 1 through 305 of SEQ ID NO: 2.~~

Claim 2 (cancelled).

Claims 3 (currently amended). The article of manufacture of ~~claim 2~~ claim 1 wherein said active Raf protein is cRaf (SEQ ID NO: 2).

Claim 4 (cancelled).

Claim 5 (currently amended). The article of manufacture of ~~claim 2~~ claim 1 wherein said active Raf protein is Raf-caax (SEQ ID NO: 7).

Claim 6 (currently amended). The article of manufacture of ~~claim 2~~ claim 1 wherein said tissue has poor circulation.

Claims 7-13 (cancelled).

Claim 14 (previously presented). The article of manufacture of claim 1 wherein said pharmaceutical composition is administered to a patient by intravenous, transdermal, intrasynovial, intramuscular, or oral administration.

Claim 15 (previously presented). The article of manufacture of claim 1 wherein said pharmaceutical composition is administered to a patient as a single dose intravenously.

Claims 16-40 (cancelled).

Claim 41 (currently amended). A pharmaceutical composition for stimulating angiogenesis in a target mammalian tissue ~~comprising a therapeutic amount of an isolated~~ consisting essentially of at least about 0.1 weight percent of an active Raf protein and in a pharmaceutically acceptable carrier or excipient, wherein the ~~isolated~~ active Raf protein is selected from the group consisting of c-Raf (SEQ ID NO: 2), a protein having the amino acid sequence corresponding to residues 306 through 648 of SEQ ID NO: 2, and Raf-caax (SEQ ID NO: 7).

Claims 42-67 (cancelled).